Market Overview

Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval

Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval

BMO Capital Markets picked Neurocrine Biosciences, Inc.. (NASDAQ: NBIX) to Outperform expectations on Wednesday, one day after the the U.S. Food and Drug Administration approved the pharmaceutical company’s drug for the treatment of tardive dyskinesia, a neurological disorder.

It was the first drug the FDA has ever approved for the condition, which the agency said is characterized by “repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips.”

Neurocrine shares were through the roof in early trading Wednesday, up nearly 25 percent.

BMO said the drug Ingrezza (valbenazine) has “potential for higher pricing points to upside to our $2.5 billion.”

“We maintain our $72 price target but believe three near-term events could support upside to $100,” BMO said, citing the price of the drug, its effectiveness against the competition, and its potential use to treat pediatric Tourette’s Syndrome.

Drug Treats Side Effects Of Other Drugs

The FDA said tardive dyskinesia is a serious side effect sometimes seen in patients who have been treated with antipsychotic medications for conditions such as schizophrenia and bipolar disorder. Tardive dyskinesia can also occur in patients taking antipsychotic medications for depression and certain medications for gastrointestinal disorders and other conditions.

The FDA said efficacy of Ingrezza was shown in a clinical trial of 234 participants that compared Ingrezza to a placebo. After six weeks, participants who received Ingrezza had improvement in the severity of abnormal involuntary movements compared to those who received a placebo.

"Tardive dyskinesia can be disabling and can further stigmatize patients with mental illness," said Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. "Approving the first drug for the treatment of tardive dyskinesia is an important advance for patients suffering with this condition."

The stock traded recently at $50.69, up about 21 percent.

Latest Ratings for NBIX

May 2020Canaccord GenuityMaintainsBuy
May 2020MizuhoMaintainsNeutral
May 2020BarclaysMaintainsEqual-Weight

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings


Related Articles (NBIX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Upgrades Health Care FDA Top Stories Analyst Ratings Best of Benzinga

Latest Ratings

BRCB of A SecuritiesMaintains44.0
FIVEB of A SecuritiesMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at